PANDAPancreatic Cancer Detection AI

Endpoint catalogActive studySynthetic mock data

Endpoints

RECIST measurements, biomarker cutoffs, time-to-event, and safety signals tracked across protocols.

On track

5

On track

At risk

1

At risk

Met

2

Met

Blocked

1

Blocked

RECIST

3 endpoints

Median progress 70%

Confirmed objective response (RECIST 1.1)

Two cases pending second read

P3-PDA-C1432, Arm A

≥ 32% by week 24

28%

88%

Confirmed objective response (RECIST 1.1)

Locked at week 24 cut

P3-PDA-C1432, Arm B

≥ 18% by week 24

21%

100%

Pathologic complete response

Enrollment paused — DSMB hold

P2-PANC-G0633

≥ 15%

Paused

22%

Biomarker

1 endpoint

Median progress 78%

ctDNA clearance (MRD-)

Vendor delay on Q2 panel

P2-CRC-D0918

≥ 60% by week 16

47%

78%

TTE

2 endpoints

Median progress 37%

Recurrence-free survival

Final analysis 2027-Q4

P2-CRC-D0918

Median ≥ 24 mo

Immature

32%

Time-to-HCC detection

Quarterly imaging review

OBS-LIVER-F4407 high-risk

Median ≥ 18 mo

Immature

41%

Safety

2 endpoints

Median progress 95%

Grade ≥3 treatment-related AE rate

DSMB review scheduled

P3-PDA-C1432, both arms

< 35%

31%

89%

DLT rate at cycle 2

Cleared to expand

P1b-HCC-E0210, dose level 3

< 33%

16%

100%

PRO

1 endpoint

Median progress 64%

EORTC QLQ-C30 global health

Wk 16 collection in progress

P3-PDA-C1432

No clinically meaningful decline

Stable

64%